Clinical trials: Fibroblast
Neoplasms
18F-FAPI-RGD PET/CT in Various Tumor Types
The clinical feasibility of 18F-FAPI-RGD PET/CT will be evaluated in 100 patients with various types of tumor, and the results will be compared with those of 18F-FDG.
- Trial name
- NCT06094530
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sichuan Provincial People's Hospital
Hypochondroplasia
Prospective Clinical Assessment Study in Children With Hypochondroplasia
This is a long-term, multicenter, non-interventional study of children ages 2.5 to <17 years with hypochondroplasia (HCH).
- Trial name
- HCH (NCT06410976)
- Where
- 25 sites in United States, Australia and 8 more
- Volunteers
- 150 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Secondary Hyperparathyroidism
FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
FGF-23 is a newly described protein that is an important regulator of phosphorus in the body. This protein increases in people with kidney disease and people who need dialysis have very high levels of FGF-23 in the blood.
- Trial name
- NCT00999037
- Testing
- Sevelamer Carbonate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of California, Los Angeles
Pancreatic Cancer
Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00900016
- Testing
- protein expression analysis, western blotting, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Fox Chase Cancer Center
Primary Immunodeficiency, DOCK8
Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Background: National Institutes of Health (NIH) researchers have been studying immune cells (white blood cells) to better understand how the human body s defense system works and adjusts or regulates itself, and how changes in…
- Conditions
- Primary Immunodeficiency, DOCK8, Virus Susceptibility
- Trial name
- NCT00895271
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Achondroplasia
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
This is a Phase 2, multicenter, randomized, placebo-controlled study to evaluate the safety and efficacy of infigratinib in participants < 3 years old with ACH.
- Trial name
- NCT07169279
- Testing
- Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration
- Where
- 12 sites in United States, Australia and 5 more
- Volunteers
- 77 people
- Sponsor
- QED Therapeutics, a BridgeBio company
PolG, Primary Mitochondrial Myopathy
Prospective Natural History Study of POLG Disease
The PIONEER study is a prospective, natural history study dedicated to characterizing the clinical progression of POLG-related disorders.
- Trial name
- PIONEER (NCT07775872)
- Where
- 21 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- The POLG Foundation
Hepatocellular Carcinoma
Primary Culture of Residual Specimens Obtained From Aspiration of Hepatic Tumor to Predict the Prognosis of the Patients
The aim of this project is to investigate whether the proliferative speeds of cultured cells using our method can be integrated into Barcelona Clinic Liver Cancer (BCLC) staging classification for the possibility of personalized…
- Trial name
- NCT02587793
- Testing
- not interventional study
- Where
- 2 sites in Taiwan
- Volunteers
- 208 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Autism, Tuberous Sclerosis
Studies of Autistic Patients: Gene Networks and Clinical Subtypes
Background: Researchers who are studying autism spectrum disorders are interested in developing a collection of research samples from both children with autism and healthy individuals, some of whom may be related to the children…
- Trial name
- NCT01092208
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Bladder Cancer
Antiangiogenic Effects of BCG on Urinary Concentration of Angiogenic Factors
To determine if there is an association between basic fibroblast growth factor,vascular endothelial growth factor, and interleukin levels and a patients response to BCG treatment ( as standard treatment)in the urine of patients…
- Trial name
- NCT00216814
- Where
- Canada
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Leukemia
Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine
This research study is to determine the safety and dosage of special cells that may make the patients own immune system fight the leukemia.
- Trial name
- NCT00058799
- Testing
- Dose Level 1, Dose Level 2, Dose Level 3
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Baylor College of Medicine
Achondroplasia
A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children and adolescents with achondroplasia (ACH) who have completed at least 26 weeks of…
- Trial name
- PROPEL3 (NCT06164951)
- Testing
- Infigratinib 0.25 mg/kg/day
- Where
- 27 sites in United States, Argentina and 8 more
- Volunteers
- 114 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Advanced Cancers and FGFR Genetic Alterations
Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options
The purpose of this program is to provide participants an early access to erdafitinib prior to market authorization (that is, Food and Drug Administration [FDA] approval in the United States).
- Trial name
- NCT03825484
- Testing
- Erdafitinib
- Sponsor
- Janssen Scientific Affairs, LLC
Epidermolysis Bullosa
A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing
The purpose of this study is to evaluate the efficacy and safety of ABH001 in the treatment of patients with epidermolysis bullosa who have wounds that are not healing.
- Trial name
- NCT01749306
- Testing
- ABH001, Control wound treatment
- Where
- 14 sites in United States, Austria and 6 more
- Volunteers
- 1 people
- Sponsor
- Shire Regenerative Medicine, Inc.
Chronic Granulomatous Disease
Generation of Powerful Biological Tools for Understanding the Pathophysiology of Chronic Granulomatous Disease.
Chronic granulomatous disease (CGD) is a rare genetic disease of innate immune due to the malfunction of phagocytic cells unable to destroy pathogens during infection.
- Trial name
- FIBRO CGD (NCT02926963)
- Testing
- samples collection : hair and skin biopsy
- Where
- France
- Volunteers
- 3 people
- Sponsor
- University Hospital, Grenoble
Osteomalacia
Serum FGF-23 and Vitamin D Deficiency
We aimed to determine the effect of vitamin D replacement therapy on serum FGF-23 concentrations in vitamin D deficient women and to compare the FGF-23 concentrations of vitamin D deficient patients with healthy subjects and…
- Trial name
- NCT01102751
- Where
- Turkey (Türkiye)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Istanbul University
Growth Disorders
Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23, a Known Phosphaturic Agent
The purpose of this study is to evaluate the effect of growth hormone treatment on phosphorus levels in the body. Phosphorus is an important mineral for bone growth.
- Trial name
- NCT00334945
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Epidermolysis Bullosa Dystrophica, Recessive
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
The purpose of this study is to evaluate the safety of FCX-007, evaluate Type VII collagen (COL7) expression and the presence of anchoring fibrils and to analyze wound healing as a result of FCX-007 administration in subjects…
- Trial name
- NCT02810951
- Testing
- FCX-007
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Castle Creek Biosciences, LLC.
Breast Cancer
Role of FGF21 in Breast Cancer
The present study aims to evaluate the serum level of FGF-21 in patients with breast cancer and its correlation with clinical, laboratory, and pathological data.
- Trial name
- NCT07113418
- Testing
- ELISA
- Where
- Egypt
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Assiut University
Alzheimer's Disease, Nervous System Disease
Genetic Studies in Alzheimer's Disease
Alzheimer's disease is a condition marked by the deterioration of mental function. The disease usually begins in late middle life and results in death in 5 to 10 years.
- Trial name
- NCT00001235
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)